Focused On-demand Library for Adenosine deaminase

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
P00813

UPID:
ADA_HUMAN

ALTERNATIVE NAMES:
Adenosine aminohydrolase

ALTERNATIVE UPACC:
P00813; Q53F92; Q6LA59

BACKGROUND:
The enzyme adenosine deaminase, with its alternative name adenosine aminohydrolase, is integral to purine metabolism, ensuring proper adenosine levels and contributing to immune system regulation. It supports T-cell activation, affects dendritic cell functionality, and modulates adenosine receptor activity, playing a crucial role in cellular communication and defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Deficiency in adenosine deaminase underpins severe combined immunodeficiency, highlighting the enzyme's critical role in immune competence. Exploring adenosine deaminase's therapeutic potential could lead to breakthroughs in treating this life-threatening disorder, emphasizing the importance of its study in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.